Syndicate this blog
BioMS Medical Begins Enrollment for Relapsing Remitting Multiple Sclerosis Drug Study
Posted 2006-11-24 12:51:06
EDMONTON, Canada | Nov 23, 2006 | BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in its placebo controlled multi-center Phase II clinical trial of MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS).
|Please send sugestions and comments to Kevin Rosenberg, M.D..|
|© 1995-2006 Kevin M. Rosenberg, M.D.|